Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2019-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2018年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2018年度独立董事述职报告" which translates to "2018 Annual Independent Director's Report." It details the independent directors' duties, attendance, opinions on company matters such as related party transactions, external guarantees, nomination and remuneration of senior management, performance forecasts, profit distribution plans, appointment of auditors, and internal control execution. The content is focused on the independent directors' report on their duties and opinions for the year 2018. This type of document is a report by the independent directors on their work and opinions, which is a specific type of management or board-related report but does not fit the categories of full annual reports (10-K), audit reports (AR), or other financial statements. It is not a simple announcement or certification but a substantive report on governance and oversight activities by independent directors. Given the nature and content, the best fitting category is Board/Management Information (MANG), which includes announcements and reports related to board activities and management changes or reports. The document length is 3625 characters, which is substantive but not extremely long, consistent with a detailed board-related report. Therefore, the classification is MANG with high confidence.
2019-04-29 Chinese
内部控制审计报告
Regulatory Filings
2019-04-29 Chinese
关于协和华东干细胞基因工程有限公司原股东业绩承诺实现情况的专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核报告" (special audit report) regarding the performance commitment realization of a specific acquisition. It includes detailed information about the acquisition of equity, performance commitments for 2017-2019, and actual performance results for 2018. The document is a specialized audit report focusing on the verification of performance commitments related to a transaction, rather than a full annual report or general financial statement. It is not a brief announcement or a presentation, but a focused audit report on a specific matter. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is short (1270 characters), but it contains substantive audit content, not just an announcement or certification, so it is not RPA or RNS. FY 2018
2019-04-29 Chinese
独立董事关于2018年度利润分配预案的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement of independent directors' opinion on the 2018 annual profit distribution plan. It references governance rules and confirms the legality and compliance of the profit distribution plan, and that it will be submitted to the annual shareholders meeting. The document is short (359 characters) and is an opinion or statement related to a specific agenda item rather than a full report or announcement of voting results. It does not contain financial statements or detailed financial data. This type of document is best classified as a Regulatory Filing (RNS) because it is a governance-related statement without full report content or voting results announcement.
2019-04-29 Chinese
关于计提资产减值准备的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's decision to make asset impairment provisions for the fiscal year ending December 31, 2018. It details the amounts of impairment for various asset categories such as accounts receivable, goodwill, patents, inventory, and fixed assets. The announcement includes the board's and independent directors' opinions on the reasonableness and compliance of the impairment provisions with accounting standards. The document is relatively short (1920 characters) and focuses on a specific accounting action rather than presenting a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or regulatory compliance filing. The content aligns with an Audit Report / Information (AR) category, as it relates to accounting principles application and impairment testing results, but is not a full annual report. Therefore, the best classification is AR (Audit Report / Information). FY 2018
2019-04-29 Chinese
九届十一次监事会会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding various approvals including the 2018 Annual Report, 2018 Annual Financial Statements, profit distribution plan, internal control evaluation report, 2019 financial budget, and the 2019 first quarter report. It includes voting results on these items and references that the full reports are available on the stock exchange website. The document itself does not contain the full financial statements or detailed financial data but rather the resolutions and approvals of these reports. It is a formal announcement of meeting decisions and approvals, not the reports themselves. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal announcement of supervisory board resolutions and approvals related to financial reports and other corporate matters, without containing the full reports or detailed financial data.
2019-04-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.